TABLE 1.
Demographics
| Stratified by diagnosis | |||
|---|---|---|---|
| Demographic | Total sample | SCD | MCI/AD |
| Participants (n) | 110 (100%) | 50 (45.5%) | 60 (55.5%) |
| Age (y) | 65.4 ± 7.4 | 65.6 ± 7.6 | 65.3 ± 7.3 |
| Sex, female (n) | 53 (48.2%) | 25 (50.0%) | 28 (46.7%) |
| Median education | 6 (range, 2–7) | 6 (range, 2–7) | 6 (range, 3–7) |
| APOE ɛ4 carrier (n) | 61 (56.5%) | 18 (37.5%) | 43 (71.7%)* |
| Aβ-positive status (n) | 79 (71.8%) | 19 (38.0%) | 60 (100%)* |
| Cognition | |||
| MMSE | 25.7 ± 4.2 | 28.8 ± 1.4 | 23.0 ± 4.0* |
| RAVLT delayed recall | 5.7 ± 4.4 | 9.3 ± 3.3 | 2.8 ± 2.8* |
| CFT animals | 19.9 ± 7.3 | 24.8 ± 5.7 | 15.6 ± 5.7* |
| Trail-making test B | 122.5 ± 83.7 | 78.0 ± 35.8 | 174.3 ± 93.4* |
| Plasma pTau181 (pg/mL) | 2.53 ± 1.14 | 2.08 ± 1.17 | 2.91 ± 0.98* |
| 18F-flortaucipir PET BPND | |||
| Entorhinal | 0.16 ± 0.26 | −0.03 ± 0.17 | 0.32 ± 0.21* |
| Temporal | 0.32 ± 0.31 | 0.10 ± 0.15 | 0.50 ± 0.29* |
| Neocortical | 0.22 ± 0.29 | 0.05 ± 0.07 | 0.36 ± 0.33* |
*
Different from SCD at P < 0.01.
Data are mean ± SD unless specified otherwise. Education reflects Dutch Verhage scale. APOE E4 was missing in 2 SCD patients, CFT animals was missing in 3 MCI/AD patients, and Trail-making test B was missing in 17 MCI/AD patients.